Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557148 | 1.00 | HSD11B1 (0.56) | HSD11B1ALDH1A1MAPK1NPC1RAB9A | |
| SCHEMBL24495732 | 0.80 | OPRL1 (0.51) | ALDH1A1MAPK1CHRM1CHRM2CHRM4 | |
| SCHEMBL2203386 | 0.75 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 | |
| SCHEMBL3100321 | 0.75 | PLD2 (0.66) | HSD11B1CHRM1 | |
| SCHEMBL1833332 | 0.74 | HSD11B1 (0.68) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 | |
| SCHEMBL5774178 | 0.73 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 | |
| SCHEMBL1760919 | 0.73 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL3106327 | 0.73 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 | |
| SCHEMBL29872667 | 0.73 | HSD11B1 (0.67) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 | |
| SCHEMBL1837629 | 0.72 | CHRM1 (0.65) | HSD11B1ALDH1A1MAPK1CHRM1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746923-A2 | DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES | FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) | 2026-05-27 | — | — | EP | claimed |
| CN-122028939-A | Thyroid hormone delivery system comprising lipid or polymer nanoparticles | 里卡尔多·泰尔齐与西尔维奥·阿尔比尼基金会 | 2026-05-12 | — | — | CN | claimed |
| WO-2025017370-A2 | DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES | FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) | 2025-01-23 | — | — | WO | claimed |
| WO-2022118966-A1 | AGENT FOR PROMOTING NUCLEIC ACID MOLECULE UPTAKE INTO CELLS, PHARMACEUTICAL COMPOSITION, AND NOVEL COMPOUND | 国立大学法人京都大学 | 2022-06-09 | — | — | WO | claimed |
| EP-4746923-A2 | DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES | FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) | 2026-05-27 | — | — | EP | disclosed |
| CN-122028939-A | Thyroid hormone delivery system comprising lipid or polymer nanoparticles | 里卡尔多·泰尔齐与西尔维奥·阿尔比尼基金会 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025017370-A2 | DELIVERY SYSTEM COMPRISING LIPID OR POLYMERIC NANOPARTICLES COMPRISING THYROID HORMONES | FONDAZIONE RICCARDO TERZI E SILVIO ALBINI (IT) | 2025-01-23 | — | — | WO | disclosed |
| EP-3752499-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2024-03-27 | — | — | EP | disclosed |
| WO-2024043242-A1 | HEART FAILURE TREATMENT VIA CARDIOTONIC EFFECT BY TRPC3/6/7 CHANNEL ACTIVATION | 国立大学法人九州大学 | 2024-02-29 | — | — | WO | disclosed |
| EP-3700902-B1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INT (DE) | 2023-03-08 | — | — | EP | disclosed |
| EP-3786160-B1 | PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-13 | — | — | EP | disclosed |
| US-11370771-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-28 | — | — | US | disclosed |
| CN-111770918-A | Inhibitors of TRPC6 | 勃林格殷格翰国际公司 | 2020-10-13 | — | — | CN | disclosed |
| US-10800757-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-13 | — | — | US | disclosed |
| EP-3700902-A1 | PYRIDINE CARBONYL DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-09-02 | — | — | EP | disclosed |
| CN-111527078-A | Pyridinecarbonyl derivatives and their therapeutic use as TRPC6 inhibitors | 勃林格殷格翰国际公司 | 2020-08-11 | — | — | CN | disclosed |
| WO-2019161010-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| WO-2019158572-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-20190169168-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-06 | — | — | US | disclosed |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169168-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | HSD11B1 3387/4885ALDH1A1 2006/4885MAPK1 1059/4885 |
| US-20190169167-A1 | INHIBITORS OF TRPC6 | TRPC6, TRPC1, TRPC7 | HSD11B1 3387/4885ALDH1A1 2006/4885MAPK1 1059/4885 |
| US-10800757-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC7 | HSD11B1 3387/4885ALDH1A1 2006/4885MAPK1 1059/4885 |
| US-11370771-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC4 | HSD11B1 3669/4885ALDH1A1 3340/4885MAPK1 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.